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Résumé en
anglais
BACKGROUND & AIMS: There is controversy over the ability of transjugular intrahepatic
portosystemic shunts (TIPS) to increase survival times of patients with cirrhosis and refractory
ascites. The high rate of shunt dysfunction with the use of uncovered stents counteracts the benefits
of TIPS. We performed a randomized controlled trial to determine the effects of TIPS with stents
covered with polytetrafluoroethylene in these patients.
METHODS: We performed a prospective study of 62 patients with cirrhosis and at least 2 large-
volume paracenteses within a period of at least 3 weeks; the study was performed at 4 tertiary care
centers in France from August 2005 through December 2012. Patients were randomly assigned to
groups that received covered TIPS (n = 29) or large-volume paracenteses and albumin as necessary
(LVP+A, n = 33). All patients maintained a low-salt diet and were examined at 1 month after the
procedure then every 3 months until 1 year. At each visit, liver disease-related complications,
treatment modifications, and clinical and biochemical variables needed to calculate Child-Pugh and
Model for End-Stage Liver Disease scores were recorded. Doppler ultrasonography was performed at
the start of the study and then at 6 and 12 months after the procedure. The primary study end point
was survival without a liver transplant for 1 year after the procedure.
RESULTS: A higher proportion of patients in the TIPS group (93%) met the primary end point than in
the LVP+A group (52%) (P = .003). The total number of paracenteses was 32 in the TIPS group vs
320 in the LVP+A group. Higher proportions of patients in the LVP+A group had portal hypertension-
related bleeding (18% vs 0%; P = .01) or hernia-related complications (18% vs 0%; P = .01) than in
the TIPS group. Patients in LVP+A group had twice as many days of hospitalization (35 days) as the
TIPS group (17 days) (P = .04). The 1-year probability of remaining free of encephalopathy was 65%
for each group.
CONCLUSIONS: In a randomized trial, we found covered stents for TIPS to increase the proportion of
patients with cirrhosis and recurrent ascites who survive transplantation-free for 1 year, compared
with patients given repeated LVP+A. These findings support TIPS as the first-line intervention in such
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